How to
Facilitate Successful Research Collaborations
Adopting
best practices and avoiding common collaboration
pitfalls
A value
proposition for your research
collaborations:
Top notch
collaborations generate strong data
Strong data leads to informed decisions
Informed decisions result in proper resource allocation
Proper resource allocation allows for new/expanded drug
usage
Wider drug usage results in better served patients
Better served patients contribute to a stronger financial
bottom line
Do you want your collaborations with outside researchers to
provide maximum value to your organization? Learn how from
Stewart Lyman, Ph.D., who headed one of the largest and
most productive Extramural Research programs in the
industry at Immunex Corporation. His presentation distills
the expertise his group developed while handling nearly 900
new and ongoing research collaborations yearly. If you want
collaborations working harder to fulfill your business and
scientific objectives, why not take advantage of his
experience?
Presentation
Topics Include:
• Philosophical
underpinnings of a successful collaboration program
• Benefits (and downsides) of extramural research
• Questions to ask when setting up a program
• Establishing formal collaboration guidelines
• Scaling up your program as your company grows
• Publication and presentation issues
• Interacting productively with collaborators
• Data storage and distribution options
• Designing a strong Material Transfer Agreement (MTA)
• The concept and best use of data gatekeepers
• Reagent packaging and shipping
• Issues for legal, clinical, and regulatory groups
• How to handle collaborators who misuse your reagents
• Working with university technology transfer groups
Questions
Answered Include:
•
What is the best method of sharing data with others in the
company?
• Are you obligated to fill all reagent requests from
academic and industry scientists?
• What is the best way to receive and handle reagent and
collaboration requests?
• Should you pay your extramural collaborators?
• Is it a good idea to send out a molecule that is already
in the clinic?
• Should you set up overlapping collaborations with
different researchers?
• At what stage of a research program is it appropriate to
send reagents to outside collaborators?
• How should you deal with negative data?
• Should you send out "surrogate" drugs?
Who
should attend:
This presentation teaches best-in-industry practices to
senior managers, research staff, and members of your legal,
clinical, development, and regulatory groups that interact
with your researchers.
Call
me at (206) 931-6403 and arrange a presentation
today!
